Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arijit Ganguli

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Clinical Therapeutics|May 23, 2015
Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid ArthritisOnur Baser, Arijit Ganguli, Sanjoy Roy, et al.
Current Medical Research and Opinion|June 3, 2017
Development of the Rheumatoid Arthritis Symptom Questionnaire (RASQ): a patient reported outcome scale for measuring symptoms of rheumatoid arthritisBenjamin Banderas, Martha Skup, Alan L Shields, et al.
Journal of Neuro-Oncology|May 24, 2013
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancerSaurabh Ray, Stacey Dacosta-Byfield, Arijit Ganguli, et al.
Clinical and Experimental Rheumatology|July 13, 2018
Short-term costs associated with non-medical switching in autoimmune conditionsAllan Gibofsky, Martha Skup, Min Yang, et al.
Rheumatology International|June 18, 2017
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspectiveM Elaine Husni, Keith A Betts, Jenny Griffith, et al.
Health Economics Review|July 26, 2015
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanySarah Neubauer, Mary Cifaldi, Thomas Mittendorf, et al.
Inquiry : a Journal of Medical Care Organization, Provision and Financing|May 27, 2017
Geographic Variation in Diagnostic Ability and Quality of Care Metrics: A Case Study of Ankylosing Spondylitis and Low Back PainJason Shafrin, Jenny Griffith, Jin Joo Shim, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid ArthritisJason Shafrin, Arijit Ganguli, Yuri Sanchez Gonzalez, et al.
Rheumatology and Therapy|October 18, 2016
Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the USVibeke Strand, Elaine Husni, Jenny Griffith, et al.
Rheumatology and Therapy|December 6, 2017
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United StatesChristina A Spivey, Jenny Griffith, Cameron Kaplan, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Clinical Therapeutics|May 23, 2015
Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid ArthritisOnur Baser, Arijit Ganguli, Sanjoy Roy, et al.
Current Medical Research and Opinion|June 3, 2017
Development of the Rheumatoid Arthritis Symptom Questionnaire (RASQ): a patient reported outcome scale for measuring symptoms of rheumatoid arthritisBenjamin Banderas, Martha Skup, Alan L Shields, et al.
Journal of Neuro-Oncology|May 24, 2013
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancerSaurabh Ray, Stacey Dacosta-Byfield, Arijit Ganguli, et al.
Clinical and Experimental Rheumatology|July 13, 2018
Short-term costs associated with non-medical switching in autoimmune conditionsAllan Gibofsky, Martha Skup, Min Yang, et al.
Rheumatology International|June 18, 2017
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspectiveM Elaine Husni, Keith A Betts, Jenny Griffith, et al.
Health Economics Review|July 26, 2015
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanySarah Neubauer, Mary Cifaldi, Thomas Mittendorf, et al.
Inquiry : a Journal of Medical Care Organization, Provision and Financing|May 27, 2017
Geographic Variation in Diagnostic Ability and Quality of Care Metrics: A Case Study of Ankylosing Spondylitis and Low Back PainJason Shafrin, Jenny Griffith, Jin Joo Shim, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid ArthritisJason Shafrin, Arijit Ganguli, Yuri Sanchez Gonzalez, et al.
Rheumatology and Therapy|October 18, 2016
Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the USVibeke Strand, Elaine Husni, Jenny Griffith, et al.
Rheumatology and Therapy|December 6, 2017
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United StatesChristina A Spivey, Jenny Griffith, Cameron Kaplan, et al.
Pageof 7